Results 111 to 120 of about 1,448,905 (180)
Background: Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib, the first BTK inhibitor approved, is associated with serious toxicities including atrial fibrillation ...
doaj +1 more source
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He +4 more
wiley +1 more source
Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang +4 more
wiley +1 more source
Location of the analyzed mutation and a schema of the involved pathway.
TIRAP, TIR domain containing adaptor protein; IRAK, IL-1 receptor-associated kinase; BTK, Bruton’s tyrosine kinase; TRAF, tumor necrosis factor receptor-associated factor; TAK, TGF-β-activated kinase; TAB, TAK binding protein; IκB, inhibitor κB; IKK, IκB
Kenjiro Mitsuhashi (480070) +9 more
core +1 more source
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan +8 more
wiley +1 more source
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari +28 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Thermodynamic characterisation of covalent ligand binding
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman +4 more
wiley +1 more source
ABSTRACT CAR‐T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose‐relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response.
Dolapo Odujinrin, Graham McClelland
wiley +1 more source

